Nadir neutrophil counts in patients with treated for breast cancer with doxorubicin and cyclophosphamide

Othieno-Abinya, NA; Nyabola, LO; Nyong'o, A; Baraza, R

doi:10.4314/eamj.v78i7.9011

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although cyclosporine and steroids may not significantly impair function of cells responsible for innate immunity [20], some myeloablative agents like cyclophosphamide (CP) can transiently deplete the neutrophil pool [21] rendering a patient defenseless against infection. CP is widely used for treatment of autoimmune diseases [22-24] and leukemias [25].…”

Section: Introductionmentioning

confidence: 99%

Effects of prophylactic administration of bacteriophages to immunosuppressed mice infected with Staphylococcus aureus

et al. 2009

View full text Add to dashboard Cite

BackgroundBacteriophages can be successfully applied to treat infections caused by antibiotic-resistant bacteria. Until now no attempts have been undertaken to treat infections in immunosuppressed patients with phages. In this work we investigated the prophylactic efficacy of specific bacteriophages in CBA mice treated with cyclophosphamide (CP) and infected with Staphylococcus aureus.ResultsHigh numbers of bacterial colony-forming units in the organs as well as elevated tumor necrosis factor and interleukin-6 serum concentrations in CP-treated and S. aureus-infected mice were significantly lowered upon application of phages. The phages markedly increased the percentage of circulating neutrophils and immature cells from the myelocytic and lymphocytic lineages in CP-treated, S. aureus-infected mice as well as of myelocytes and immature neutrophils in the bone marrow. In addition, phages stimulated in such mice generation of specific agglutinins against S. aureus.ConclusionApplication of specific phages to immunosuppressed mice prior to infection with S. aureus proved very effective, suggesting a potential benefit of phage therapy in immunocompromised patients experiencing bacterial infections.

show abstract

Section: Introductionmentioning

confidence: 99%

Effects of prophylactic administration of bacteriophages to immunosuppressed mice infected with Staphylococcus aureus

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Toxicity of chemotherapeutic drugs was reported to occur in a dose‐dependent way. In patients with breast cancer, larger doses of adriamycin (60 mg/m 2 ) plus cyclophosphamide (600 mg/m 2 ) favoured the incidence and severity of neutropenia compared with smaller doses (50/500 mg/m 2 for adriamycin and cyclophosphamide respectively) (Othieno‐Abinya et al . 2001).…”

Section: Introductionmentioning

confidence: 99%

“…Toxicity of chemotherapeutic drugs was reported to occur in a dose-dependent way. In patients with breast cancer, larger doses of adriamycin (60 mg/m 2 ) plus cyclophosphamide (600 mg/m 2 ) favoured the incidence and severity of neutropenia compared with smaller doses (50/ 500 mg/m 2 for adriamycin and cyclophosphamide respectively) (Othieno-Abinya et al 2001). But other studies evaluating breast cancer women receiving adriamycin/ cyclophosphamide at smaller doses (50/500 mg/m 2 ) found neutropenia grade 4 in 68% cycles, infections in 8% and neutropenic fever in 5.5% cases (Nabholtz et al 2001).…”

Section: Introductionmentioning

confidence: 99%

Neutrophil count is not associated with infection episodes in breast cancer patients treated with anthracycline-based chemotherapy

Mendonça

Pereira

Silva

et al. 2009

European Journal of Cancer Care

View full text Add to dashboard Cite

The aim was to evaluate the impact of anthracycline-based chemotherapy on neutrophil count and infections in breast cancer women. The medical records of patients were retrospectively and prospectively reviewed (8-year period). Patients were grouped according to anthracyclines at different doses: (1) Scheme 1 (n = 56, 224 courses): 50-60 mg/m(2); and (2) Scheme 2 (n = 25, 100 courses): 65-75 mg/m(2), associated to cyclophosphamide and 5-fluorouracil, at 21-day intervals between courses. Neutrophil count was performed on diagnosis and 48-72 h before each chemotherapy course. Patients were followed up for neutrophil count and infection episodes for three consecutive courses. Multivariate analysis was used to determine independent factors for infection. After the first course, neutrophil count was reduced than baseline (P < 0.001) and maintained during the subsequent courses, without differences between courses or groups. There were 49 infection episodes (63.2% urinary, 18.4% neutropenic fever and 18.4% diverses), mainly between course 1-2 (39%) and course 3-4 (38%) of chemotherapy. Patients evaluated as presenting or not with infection episodes did not differ in neutrophil count. The number of chemotherapy courses (P < 0.05), but not age, neutrophil count or chemotherapy regimen, was associated with infection. We concluded that progressive chemotherapy, but not neutrophil count, was an independent factor for infection.

show abstract

Nadir neutrophil counts in patients with treated for breast cancer with doxorubicin and cyclophosphamide

Cited by 2 publications

References 0 publications

Effects of prophylactic administration of bacteriophages to immunosuppressed mice infected with Staphylococcus aureus

Effects of prophylactic administration of bacteriophages to immunosuppressed mice infected with Staphylococcus aureus

Neutrophil count is not associated with infection episodes in breast cancer patients treated with anthracycline-based chemotherapy

Contact Info

Product

Resources

About